grt-c903
Vaccineexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 31, 2019 (NCT03953235)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06253520 | Phase 1 | May 16, 2024 | National Cancer Institute (NCI) |
| NCT03953235 | Phase 1/Phase 2 (Phase 2) | Jul 31, 2019 | Gritstone Oncology, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gritstone Oncology, Inc. | For profit | 1 | 1 | 1 | 2019 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2024 |
2 organizations
Page 1 / 1